DOI:

Real-world European experience with the transcatheter treatment of significant mitral regurgitation: demographics and procedural outcomes

Corti R.1, Butter C.2, Baldus S.3, Schillinger W.4, Kuck K.H.5, Hausleiter J.6, Maisano F.7, Schofer J.8, Ince H.9, Van Der Heyden J.10, Ussia G.P.11, Schäfer U.12, Kowalski M.13, Boekstegers P.14, Bekeredjian R.15, Hoffmann R.16, Franzen O.17

Transcatheter therapies in patients with mitral regurgitation or poor left ventricular function

Real-world European experience with the transcatheter treatment of significant mitral regurgitation: demographics and procedural outcomes

Aims: Use of the MitraClip System as a transcatheter therapeutic option for treating significant mitral regurgitation (MR) continues to expand throughout Europe. As of June 15, 2012, a total of 4,534 patients have been treated with the MitraClip devices in Europe in a real-world setting in both the ACCESS-EUROPE studies and in commercial use.

Methods and results: Baseline demographics, device time and post-procedural reduction in MR severity are reported from patients treated between September 17, 2008 and June 15, 2012. A total of 4,534 patients were treated at 144 institutions in 17 European countries. Patients were elderly, with a median age of 75 years. At baseline, 67% of patients had functional MR (FMR). Left ventricular (LV) dysfunction was categorised as severe in 34% of patients, with LV ejection fraction <30% reported in 30% of patients. Pre-procedural MR severity was reported as MR ≥3+ in 99.6% of patients. The MitraClip device implant rate was 95.6% with the following distribution of devices: 201 patients (4.4%) underwent the procedure but received no device, 2,873 patients (63.4%) received one device, 1,350 patients (29.8%) received two devices and 110 patients (2.4%) received three or more devices. The median device time was 80 minutes. Post-procedural MR severity was reported as MR ≤2+ in 90% of patients, with 58% of all patients achieving MR ≤1+. Approximately 93% of patients achieved at least a 1-grade reduction in MR severity. No change in MR severity was reported in 5.6% of patients and <1% of patients had worsening MR severity.

Conclusions: As reported, patients treated with the MitraClip device in the real-world use setting are elderly and present with a significant incidence of FMR and impaired LV function. Reduction of MR severity was achieved via the MitraClip therapy in the majority of these patients, demonstrating adoption of the MitraClip therapy in a predominantly high-surgical-risk patient population.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

On the same subject

Editorial

10.4244/EIJ-E-23-00052 Mar 18, 2024
Comparative preclinical assessment of drug-coated balloons: a blessing and a curse for clinical translation
Joner M and Wild L
free

Debate

10.4244/EIJ-E-24-00005 Mar 18, 2024
Ischaemic and viability testing for guiding PCI are overrated: pros and cons
McEntegart M et al
free

Original Research

10.4244/EIJ-D-23-00783 Mar 18, 2024
Redo-TAVI with the ACURATE neo2 and Prime XL for balloon-expandable transcatheter heart valve failure
Meier D et al
Trending articles
281.53

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
243.2

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
208.35

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.7

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.03

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved